SolEmuls technology: a way to overcome the drawback of parenteral administration of insoluble drugs. - Wikidata - wikimedia - TriplyDB

SolEmuls technology: a way to overcome the drawback of parenteral administration of insoluble drugs.

SolEmuls technology: a way to overcome the drawback of parenteral administration of insoluble drugs.

http://www.wikidata.org/entity/Q33304020

about

Nanoemulsions in translational research-opportunities and challenges in targeted cancer therapy How can micelle systems be rebuilt by a heating process?Injectable lipid emulsions-advancements, opportunities and challenges.

P2860

Q26858849-1F39AE3E-6D54-4963-99D4-E28091D2E46F Q35686909-DCDB6F50-EF76-4305-A55C-8266F00D92F7 Q37803157-F98C0567-A097-46E3-9019-20E0D7191411

P2860

SolEmuls technology: a way to overcome the drawback of parenteral administration of insoluble drugs.

http://www.wikidata.org/entity/Q33304020

description

2007 nî lūn-bûn

@nan

2007 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

SolEmuls technology: a way to ...... nistration of insoluble drugs.

@ast

SolEmuls technology: a way to ...... nistration of insoluble drugs.

@en

SolEmuls technology: a way to ...... nistration of insoluble drugs.

@nl

type

label

SolEmuls technology: a way to ...... nistration of insoluble drugs.

@ast

SolEmuls technology: a way to ...... nistration of insoluble drugs.

@en

SolEmuls technology: a way to ...... nistration of insoluble drugs.

@nl

prefLabel

SolEmuls technology: a way to ...... nistration of insoluble drugs.

@ast

SolEmuls technology: a way to ...... nistration of insoluble drugs.

@en

SolEmuls technology: a way to ...... nistration of insoluble drugs.

@nl

P1433

Q33304020-3F6CFEFF-B8D5-4B3B-B027-701CD083A4FB

P1476

Q33304020-CA0C6731-6A06-49F6-957D-956FFF816099

P2093

Q33304020-58814D1D-7D8E-414A-B20C-5F39DC1334DB

Q33304020-5DE47F6E-CBBE-48EE-BBCE-3AB8AF3FAFAE

Q33304020-71E46F18-B3CB-43EE-A9C3-EF61BC303261

Q33304020-A6DA9145-0A5B-46EC-85BE-FDF69D02F50B

Q33304020-CE98A251-09C3-4050-8FEB-A96B267596D4

Q33304020-CF5B8EB7-874B-412D-B5F3-CB292B6F61A3

Q33304020-F4AF6A64-8633-4353-8929-B0BF7654A2E9

P2860

Q33304020-05F6B0A7-2721-45C1-8591-75EC7023F9D1

Q33304020-0D2E0E46-1C1F-472C-8712-DD7A1608A3C6

Q33304020-51CC414E-6C2D-4ADE-8CF6-E54B4C8AF4BC

Q33304020-95822461-EB6C-4843-BF5A-E8E1A2DD37A6

Q33304020-C2D93ADF-6BEB-4763-A080-8CE01AD212E6

Q33304020-CEF87FCA-2296-4561-BA99-69397238CE07

Q33304020-F1D478F1-0758-46ED-AF9E-C40B5E38E78E

Q33304020-F40A3D11-65E9-4C98-9333-1F4DBAE1C619

P304

Q33304020-053575A2-DC5D-40C3-BEB5-33F73C881A58

P31

Q33304020-676ECC91-440E-4432-A3D3-61ABEAA53DE6

P356

Q33304020-DA50E47D-4095-4C17-BCD2-A1857F49F984

P433

Q33304020-0A998F6F-039F-4012-92AA-D831ADBB3A0B

P478

Q33304020-8DF03DAE-2A06-438C-9C19-AE79A8B75BC1

P577

Q33304020-35402DAC-7D26-4CA7-A9B4-C74D9AED2C95

P698

Q33304020-D33191B1-4243-41FA-9CC0-75AA48741914

P356

10837450701555885

P1433

Pharmaceutical Development and Technology

P1476

SolEmuls technology: a way to ...... nistration of insoluble drugs.

@en

P2093

Araújo IB

http://www.w3.org/2001/XMLSchema#string

Buttle I

http://www.w3.org/2001/XMLSchema#string

Damasceno BP

http://www.w3.org/2001/XMLSchema#string

Egito ES

http://www.w3.org/2001/XMLSchema#string

Junghanns JU

http://www.w3.org/2001/XMLSchema#string

Müller RH

http://www.w3.org/2001/XMLSchema#string

Silva AK

http://www.w3.org/2001/XMLSchema#string

P2860

SolEmuls-novel technology for the formulation of i.v. emulsions with poorly soluble drugs.

Unusual lipid structures selectively reduce the toxicity of amphotericin B.

Lipid-based amphotericin B: a review of the last 10 years of use.

Treatment of solid organ transplant patients with invasive fungal infections: should a combination of antifungal drugs be used?

Liposomes as carriers of antimicrobial agents

Amphotericin B/emulsion admixture interactions: an approach concerning the reduction of amphotericin B toxicity.

Evaluation of the relationship of the molecular aggregation state of amphotericin B in medium to its genotoxic potential.

An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis.

P304

437-445

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10837450701555885

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2007-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17963143

http://www.w3.org/2001/XMLSchema#string